Stock HALO HALOZYME THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Halozyme Therapeutics, Inc.

Equities

HALO

US40637H1095

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-26 pm EDT 		5-day change 1st Jan Change
38.57 USD +0.29% Intraday chart for Halozyme Therapeutics, Inc. -0.18% +4.36%
Apr. 25 Halozyme Therapeutics, Inc. Announces the Election of Mahesh Krishnan, M.D. to its Board of Directors CI
Apr. 18 Halozyme Therapeutics Insider Sold Shares Worth $768,390, According to a Recent SEC Filing MT

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 2,591 5,765 5,659 7,694 4,882 4,900 - -
Enterprise Value (EV) 1 2,874 6,014 5,794 8,837 6,046 5,901 5,322 5,177
P/E ratio -35.5 x 46.9 x 14.7 x 39.5 x 17.6 x 12.8 x 9.46 x 7.17 x
Yield - - - - - - - -
Capitalization / Revenue 13.2 x 21.5 x 12.8 x 11.7 x 5.89 x 5.13 x 4.45 x 3.73 x
EV / Revenue 14.7 x 22.5 x 13.1 x 13.4 x 7.29 x 6.18 x 4.84 x 3.94 x
EV / EBITDA -45.2 x 40.8 x 20.8 x 28.1 x 14.2 x 10.8 x 7.94 x 6.23 x
EV / FCF -32.1 x 114 x 19.4 x 37.6 x - 12.5 x 8.8 x 7.02 x
FCF Yield -3.11% 0.88% 5.14% 2.66% - 8.03% 11.4% 14.3%
Price to Book 26.4 x 38.2 x 28.1 x 45.3 x - 8.66 x 4.89 x 3.87 x
Nbr of stocks (in thousands) 146,142 134,972 140,725 135,213 132,098 127,054 - -
Reference price 2 17.73 42.71 40.21 56.90 36.96 38.57 38.57 38.57
Announcement Date 2/24/20 2/23/21 2/22/22 2/21/23 2/20/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 196 267.6 443.3 660.1 829.3 954.4 1,100 1,312
EBITDA 1 -63.54 147.5 278.9 315 426.2 544.1 670.1 831.1
EBIT 1 -67.61 144.3 275.9 267.5 337.6 474.9 619.5 820.5
Operating Margin -34.5% 53.91% 62.24% 40.53% 40.71% 49.75% 56.31% 62.52%
Earnings before Tax (EBT) 1 -72.25 129.3 248.5 248.9 348.3 472.4 624 822.6
Net income 1 -72.24 129.1 402.7 202.1 281.6 369.7 483.7 628.5
Net margin -36.86% 48.24% 90.84% 30.62% 33.96% 38.74% 43.97% 47.89%
EPS 2 -0.5000 0.9100 2.740 1.440 2.100 3.017 4.077 5.382
Free Cash Flow 1 -89.46 52.95 298 235.3 - 474 604.5 738
FCF margin -45.65% 19.79% 67.22% 35.65% - 49.66% 54.95% 56.23%
FCF Conversion (EBITDA) - 35.89% 106.84% 74.7% - 87.12% 90.2% 88.8%
FCF Conversion (Net income) - 41.02% 73.99% 116.41% - 128.2% 124.97% 117.41%
Dividend per Share - - - - - - - -
Announcement Date 2/24/20 2/23/21 2/22/22 2/21/23 2/20/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1
Net sales 1 115.8 102 117.3 152.4 209 181.5 162.1 221 216 230 200.8 208 253.1 291.7 242.7
EBITDA 1 81.74 57.31 81.19 40.84 85.3 79.45 74.54 115.1 114.9 121.7 116.2 111.6 144.3 189.8 -
EBIT 1 75.59 56.53 75.67 34.06 83.29 74.51 53.8 94.46 88.28 101 90.76 94.11 135.3 155.4 144.8
Operating Margin 65.26% 55.42% 64.52% 22.35% 39.86% 41.05% 33.18% 42.73% 40.86% 43.92% 45.2% 45.24% 53.48% 53.28% 59.66%
Earnings before Tax (EBT) 1 74.11 54.81 74.41 30.01 73.71 70.79 52.24 93.16 101.8 101.2 93.3 92.83 132.8 154.6 141.3
Net income 1 216.6 66.77 60.11 22.68 61.63 57.7 39.62 74.75 81.84 85.39 72.01 71.75 105.7 125.6 113
Net margin 186.99% 65.46% 51.25% 14.89% 29.49% 31.79% 24.43% 33.82% 37.88% 37.12% 35.86% 34.49% 41.75% 43.05% 46.57%
EPS 2 1.480 0.4600 0.4300 0.1600 0.4400 0.4200 0.2900 0.5700 0.6100 0.6500 0.5867 0.6117 0.8567 0.9867 0.9400
Dividend per Share - - - - - - - - - - - - - - -
Announcement Date 11/2/21 2/22/22 5/10/22 8/9/22 11/8/22 2/21/23 5/9/23 8/8/23 11/6/23 2/20/24 - - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 282 250 136 1,143 1,163 1,001 422 277
Net Cash position 1 - - - - - - - -
Leverage (Debt/EBITDA) -4.444 x 1.691 x 0.4867 x 3.63 x 2.729 x 1.84 x 0.6296 x 0.333 x
Free Cash Flow 1 -89.5 53 298 235 - 474 605 738
ROE (net income / shareholders' equity) -42.4% 106% 169% 110% 293% 169% 91.7% 82.5%
ROA (Net income/ Total Assets) -14.4% 22.5% 34.9% 13.7% 20.8% 26.7% 28.8% 29.6%
Assets 1 503.1 572.9 1,153 1,473 1,354 1,387 1,678 2,124
Book Value Per Share 2 0.6700 1.120 1.430 1.260 - 4.450 7.890 9.960
Cash Flow per Share 2 - 0.3900 2.040 1.710 - 3.750 - -
Capex 1 4.04 2.5 1.46 4.81 - 2 2 12
Capex / Sales 2.06% 0.94% 0.33% 0.73% - 0.21% 0.18% 0.91%
Announcement Date 2/24/20 2/23/21 2/22/22 2/21/23 2/20/24 - - -
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Ratings for Halozyme Therapeutics, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
A-
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
12
Last Close Price
38.57 USD
Average target price
50.5 USD
Spread / Average Target
+30.93%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
HALOZYME THERAPEUTICS, INC. Stock Halozyme Therapeutics, Inc.
+4.36% 4.9B
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-2.31% 103B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+0.56% 95.28B
ARGENX SE Stock argenx SE
+1.69% 22.15B
BIONTECH SE Stock BioNTech SE
-17.37% 21.02B
GENMAB A/S Stock Genmab A/S
-9.30% 18.15B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-41.01% 16.74B
BEIGENE, LTD. Stock BeiGene, Ltd.
-14.85% 16.05B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+3.21% 13.68B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+33.54% 12.17B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. HALO Stock
  4. Financials Halozyme Therapeutics, Inc.